Zacks: Analysts Anticipate Prestige Consumer Healthcare Inc. (NYSE:PBH) Will Announce Quarterly Sales of $230.27 MillionFebruary 20, 2021 0 By administrator
Equities analysts predict that Prestige Consumer Healthcare Inc. (NYSE:PBH) will report $230.27 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Prestige Consumer Healthcare’s earnings. The highest sales estimate is $231.80 million and the lowest is $228.90 million. Prestige Consumer Healthcare reported sales of $251.24 million during the same quarter last year, which would suggest a negative year over year growth rate of 8.3%. The business is expected to announce its next quarterly earnings results on Thursday, May 6th.
On average, analysts expect that Prestige Consumer Healthcare will report full year sales of $935.90 million for the current year, with estimates ranging from $934.50 million to $937.40 million. For the next fiscal year, analysts forecast that the business will report sales of $950.23 million, with estimates ranging from $939.00 million to $970.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Wednesday, February 3rd. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.04. The firm had revenue of $238.80 million during the quarter, compared to analyst estimates of $231.55 million. Prestige Consumer Healthcare had a net margin of 17.03% and a return on equity of 13.76%. Prestige Consumer Healthcare’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.81 EPS.
A number of research analysts have issued reports on the stock. BMO Capital Markets raised shares of Prestige Consumer Healthcare to an “outperform” rating and set a $125.00 target price for the company in a research note on Wednesday, December 2nd. CIBC upped their price target on shares of Prestige Consumer Healthcare from $100.00 to $103.00 and gave the stock a “neutral” rating in a research note on Monday, November 9th. DA Davidson reduced their price target on shares of Prestige Consumer Healthcare from $45.00 to $39.00 and set a “neutral” rating for the company in a research note on Friday, November 6th. Finally, TD Securities upped their price target on shares of Prestige Consumer Healthcare from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $74.29.
Prestige Consumer Healthcare stock opened at $41.33 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.98 and a debt-to-equity ratio of 1.22. The firm has a 50-day moving average price of $39.61 and a…